Moderna Cancer Vaccine Shows Promising Results in Melanoma Trial
Summary
Moderna's personalized mRNA cancer vaccine has shown encouraging results in a melanoma trial when combined with Merck's Keytruda. The treatment reduced the risk of cancer recurrence and sent Moderna's share price sharply higher.
Key Points
- Moderna and Merck said the personalized mRNA vaccine plus Keytruda met the primary goal in the latest phase of melanoma trials.
- The treatment showed promising results in reducing recurrence risk and may also help prevent cancer from spreading.
- The trial involved 1,137 high-risk melanoma patients whose tumors were analyzed to create individualized vaccines.
- Moderna's stock jumped sharply after the results were announced, highlighting the treatment's business potential.
